PURPOSE: To investigate the efficacy of chemotherapy followed by low-dose involved-field radiotherapy for the treatment of @entity2971 (GCTs). @entity1 AND METHODS: Thirty-three @entity1 with GCTs, including 16 @entity3438 , 11 @entity1 chorionic gonadotropin-beta ( @entity6740 -beta)-secreting @entity3438 , three mixed GCTs composed of immature @entity3438 (IMT/G), and three highly malignant mixed GCTs, were treated. @entity2879 and @entity900 (EP) were used for the treatment of solitary @entity3438 , and @entity1260 , @entity900 , and @entity2879 (ICE) were used for the treatment of other GCTs. The dose schedule was 24 Gy for @entity3438 and 40 to 54 Gy for other GCTs. An involved-field set-up was used except for highly malignant GCTs, in which craniospinal irradiation was used. The median follow-up was 58 months (range, 18 to 102 months). RESULTS: Disease-related, overall, and relapse-free survival rates at 5 years were 100%, 93%, and 69% for all @entity1 , 100%, 100%, and 86% for @entity1 with @entity3438 , and 100%, 75%, and 44% for @entity1 with @entity7103 , respectively. All six @entity1 with nongerminomatous GCTs were alive at the last follow-up. All eight relapses (one pure @entity3438 , five @entity7103 , and two IMT/G), except one in a course of salvage treatment, were salvaged and free of disease at the last follow-up. No decline was observed in the full-scale, verbal, or performance intelligence quotient at 12 to 51 months after the treatment in 11 @entity1 . CONCLUSION: Our results support an excellent prognosis after EP and ICE regimens followed by radiotherapy. Dose and volume can be reduced to 24 Gy in 12 fractions and involve a field set-up after EP chemotherapy for the treatment of @entity3438 .

Induction chemotherapy followed by low-dose involved-field radiotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'PATIENTS'] @entity7103 :: ('MESH:C535764', 'Disease') :: ['HCG-beta-secreting germinomas'] @entity2971 :: ('MESH:D009373', 'Disease') :: ['intracranial germ cell tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity6740 :: ('MESH:C538388', 'Disease') :: ['HCG'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide', 'Etoposide'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity3438 :: ('MESH:D018237', 'Disease') :: ['pure germinomas', 'teratomas plus germinomas', 'germinoma', 'germinomas']
@entity2971 :: (MESH:D009373,Disease) :: ['intracranial germ cell tumors']
